News

PPD has entered an agreement with Janssen Pharmaceutica to develop and commercialise two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other

Simcere Pharmaceutical revenue increases to RMB 443.7m for the third quarter of 2009 compared to RMB 443.4m for the same period last year. Revenue from Endu amounted to

Spherix has reported positive interim Phase 3 clinical results for the planned review of the NEET (Naturlose (D-tagatose) Efficacy Evaluation Trial) trial of D-tagatose in drug naive patients.

CardioComm Solutions has signed a software development agreement with MD Primer, under which MD Primer has retained CardioComm to develop a new software platform of the GlobalCardio, GEMS,

Sinovac Biotech has reported that it was selected by the Shanghai government to supply its inactivated hepatitis A vaccine, Healive, in Shanghai. Out of the five vaccine manufacturers

PanGenetics, developing PG110, a humanised antibody to Nerve Growth Factor (NGF), has entered into an agreement with Abbott. Under the agreement Abbott will acquire the global rights to

Merck & Co. has expressed its confidence in the safety and efficacy profiles of Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin). The results of ARBITER 6 were widely predicted because

Amunix and Versartis have reported that the scientific journal Nature Biotechnology has published a comprehensive paper entitled ‘A recombinant polypeptide extends the in vivo half-life of peptides and

Bristol-Myers Squibb has announced that it will split off its holdings in Mead Johnson Nutrition. The company expects the split-off to be a tax-advantaged way to further deliver